Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

NCT06640166 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Carcinoma
Colorectal Neoplasms
Colorectal Tumor
Colorectal Adenocarcinoma
Colorectal Cancer (CRC)
Colorectal Cancer
Colon Cancer
Colon Adenocarcinoma
Colon Carcinoma
Colon Neoplasm

Interventions

DRUG: encorafenib + cetuximab + FOLFIRI

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborators

[object Object]